Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2023 Jun 15

PMID 37318710

Authors

Michele Wilson

Cheryl McDade

Anna Trisia Beby-Heijtel

Angela Waterval-Overbeek

Vishalini Sundaram

Johnna Perdrizet

Affiliations

Soon will be listed here.

Abstract

Introduction: The 10-valent pneumococcal conjugate vaccine (PCV10, Synflorix) was introduced into the Dutch pediatric national immunization program (NIP) starting in 2011. However, there is substantial pneumococcal disease burden due to increases in non-PCV10 covered serotypes. Higher-valent vaccines for pediatrics (PCV13, PCV15, and PCV20) may alleviate much of the remaining disease burden upon implementation through broader serotype coverage. This article assesses the public health impact of different pediatric vaccination strategies (switching to PCV13, PCV15 or PCV20) versus maintaining PCV10 at different time intervals in the Netherlands.

Methods: A population-based, decision-analytic model was developed using historical pneumococcal disease surveillance data to forecast future invasive pneumococcal disease (IPD), pneumonia, and otitis media (OM) cases over a 7-year period (2023-2029) under the following strategies: continued use of PCV10, switching to PCV13 in 2023, switching to PCV15 in 2023, and switching to PCV20 in 2024. Scenario analyses were performed to account for uncertainties in future serotype distributions, disease incidence reductions, and epidemiologic parameters.

Results: Switching to PCV13 in 2023 was found to avert 26,666 cases of pneumococcal disease compared to continuing PCV10 over a 7-year period (2023-2029). Switching to PCV15 in 2023 was found to avert 30,645 pneumococcal cases over the same period. Switching to PCV20 once available in 2024 was estimated to avert 45,127 pneumococcal cases from 2024-2029. Overall conclusions were maintained after testing uncertainties.

Conclusions: For the Dutch pediatric NIP, switching to PCV13 in 2023 would be an effective strategy compared with continued use of PCV10 for averting pneumococcal disease cases. Switching to PCV20 in 2024 was estimated to avert the most pneumococcal disease cases and provide the highest protection. However, in the face of budget constraints and the undervaluation of prevention strategies, it remains challenging to implement higher valent vaccines. Further research is needed to understand the cost-effectiveness and feasibility of a sequential approach.

Citing Articles

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme.

Cakar E, Ta A, Peters M, Vinand E, Waterval-Overbeek A, Ilic A Infect Dis Ther. 2025; .

PMID: 39915436 DOI: 10.1007/s40121-025-01109-2.

The global burden of otitis media in 204 countries and territories from 1992 to 2021: a systematic analysis for the Global Burden of Disease study 2021.

Huang G, Lin B, Li P, Tang N, Fan Z, Lu B Front Public Health. 2025; 12:1519623.

PMID: 39906401 PMC: 11790571. DOI: 10.3389/fpubh.2024.1519623.

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit.

Perdrizet J, Ta A, Huang L, Wannaadisai W, Ilic A, Hayford K Infect Dis Ther. 2025; .

PMID: 39899200 DOI: 10.1007/s40121-025-01108-3.

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population.

Fridh A, Palmborg A, Ta A, Freigofaite D, Warren S, Perdrizet J Hum Vaccin Immunother. 2024; 20(1):2400751.

PMID: 39279284 PMC: 11407408. DOI: 10.1080/21645515.2024.2400751.

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis.

Ta A, Kuhne F, Laurenz M, von Eiff C, Warren S, Perdrizet J Infect Dis Ther. 2024; 13(6):1333-1358.

PMID: 38733494 PMC: 11128430. DOI: 10.1007/s40121-024-00977-4.

References

Mangen M, Rozenbaum M, Huijts S, van Werkhoven C, Postma D, Atwood M . Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015; 46(5):1407-16. PMC: 4750466. DOI: 10.1183/13993003.00325-2015. View

Ladhani S, Collins S, Djennad A, Sheppard C, Borrow R, Fry N . Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018; 18(4):441-451. DOI: 10.1016/S1473-3099(18)30052-5. View

van Hoek A, Choi Y, Trotter C, Miller E, Jit M . The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012; 30(50):7205-13. DOI: 10.1016/j.vaccine.2012.10.017. View

Lochen A, Croucher N, Anderson R . Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020; 10(1):18977. PMC: 7643077. DOI: 10.1038/s41598-020-75691-5. View

Bloom D, Kirby P, Pugh S, Stawasz A . Commentary: Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? The Perils of Undervaluation. Pediatr Infect Dis J. 2019; 39(2):145-156. DOI: 10.1097/INF.0000000000002521. View

Dagan R, Givon-Lavi N, Shkolnik L, Yagupsky P, Fraser D . Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: implication for immunizing with conjugate vaccines. J Infect Dis. 2000; 181(4):1322-9. DOI: 10.1086/315383. View

Hullegie S, Schilder A, Marchisio P, de Sevaux J, van der Velden A, van de Pol A . A Strong Decline in the Incidence of Childhood Otitis Media During the COVID-19 Pandemic in the Netherlands. Front Cell Infect Microbiol. 2021; 11:768377. PMC: 8591181. DOI: 10.3389/fcimb.2021.768377. View

Ben-Shimol S, Regev-Yochay G, Givon-Lavi N, van der Beek B, Brosh-Nissimov T, Peretz A . Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Clin Infect Dis. 2021; 74(9):1639-1649. DOI: 10.1093/cid/ciab645. View

Peckeu L, van der Ende A, de Melker H, Sanders E, Knol M . Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands. Vaccine. 2020; 39(2):431-437. DOI: 10.1016/j.vaccine.2020.11.018. View

10.

Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling M . Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2016; 5(1):e51-e59. DOI: 10.1016/S2214-109X(16)30306-0. View

11.

. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005; 54(36):893-7. View

12.

Wilson M, McDade C, Perdrizet J, Mignon A, Farkouh R, Wasserman M . Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium. Infect Dis Ther. 2021; 10(3):1765-1778. PMC: 8322259. DOI: 10.1007/s40121-021-00485-9. View

13.

Thorrington D, van Rossum L, Knol M, de Melker H, Rumke H, Hak E . Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS One. 2018; 13(2):e0192640. PMC: 5806887. DOI: 10.1371/journal.pone.0192640. View

14.

Perdrizet J, Santana C, Senna T, Alexandre R, Sini de Almeida R, Spinardi J . Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2020; 17(4):1162-1172. PMC: 8018448. DOI: 10.1080/21645515.2020.1809266. View

15.

Shafie A, Ahmad N, Naidoo J, Foo C, Wong C, Pugh S . Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Hum Vaccin Immunother. 2020; 16(7):1719-1727. PMC: 7482775. DOI: 10.1080/21645515.2019.1701911. View

16.

Wilson M, Wasserman M, Jadavi T, Postma M, Breton M, Peloquin F . Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infect Dis Ther. 2018; 7(3):353-371. PMC: 6098750. DOI: 10.1007/s40121-018-0206-1. View

17.

Wilson M, Wasserman M, Breton M, Peloquin F, Earnshaw S, McDade C . Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis. Infect Dis Ther. 2020; 9(2):341-353. PMC: 7237628. DOI: 10.1007/s40121-020-00294-6. View

18.

Perdrizet J, Horn E, Hayford K, Grant L, Barry R, Huang L . Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States. Infect Dis Ther. 2023; 12(5):1351-1364. PMC: 10229489. DOI: 10.1007/s40121-023-00798-x. View

19.

Melegaro A, Edmunds W, Pebody R, Miller E, George R . The current burden of pneumococcal disease in England and Wales. J Infect. 2005; 52(1):37-48. DOI: 10.1016/j.jinf.2005.02.008. View

20.

Pilishvili T, Lexau C, Farley M, Hadler J, Harrison L, Bennett N . Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2009; 201(1):32-41. DOI: 10.1086/648593. View